Robert W. Baird Increases Twist Bioscience (NASDAQ:TWST) Price Target to $40.00

Twist Bioscience (NASDAQ:TWST) had its price objective lifted by Robert W. Baird from $39.00 to $40.00 in a research report report published on Friday morning, Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other equities analysts also recently issued reports on the company. Barclays reduced their price target on Twist Bioscience from $45.00 to $40.00 and set an overweight rating on the stock in a research report on Wednesday, April 10th. Scotiabank increased their price target on Twist Bioscience from $30.00 to $43.00 and gave the company a sector outperform rating in a research note on Monday, February 5th. Finally, The Goldman Sachs Group upgraded Twist Bioscience from a neutral rating to a buy rating and boosted their price target for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Twist Bioscience presently has an average rating of Buy and a consensus target price of $41.67.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST opened at $41.60 on Friday. The business has a fifty day moving average price of $34.03 and a 200 day moving average price of $31.14. Twist Bioscience has a 1-year low of $11.81 and a 1-year high of $43.21.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.05. The business had revenue of $75.30 million for the quarter, compared to analysts’ expectations of $70.70 million. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The company’s revenue was up 25.1% compared to the same quarter last year. During the same period last year, the business earned ($1.06) EPS. On average, research analysts predict that Twist Bioscience will post -3.17 EPS for the current year.

Insider Transactions at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,487 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total value of $55,658.41. Following the sale, the chief executive officer now owns 516,409 shares in the company, valued at $19,329,188.87. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Twist Bioscience news, CEO Emily M. Leproust sold 1,487 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $37.43, for a total transaction of $55,658.41. Following the completion of the sale, the chief executive officer now directly owns 516,409 shares in the company, valued at approximately $19,329,188.87. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 1,128 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $33.52, for a total transaction of $37,810.56. Following the completion of the sale, the chief executive officer now owns 515,281 shares in the company, valued at approximately $17,272,219.12. The disclosure for this sale can be found here. Insiders sold a total of 13,211 shares of company stock worth $449,573 over the last three months. 3.92% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Artisan Partners Limited Partnership boosted its holdings in Twist Bioscience by 111.3% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock worth $137,241,000 after buying an additional 1,961,621 shares in the last quarter. Invesco Ltd. grew its position in shares of Twist Bioscience by 1,496.2% during the 3rd quarter. Invesco Ltd. now owns 831,006 shares of the company’s stock valued at $16,836,000 after acquiring an additional 778,944 shares during the period. ARK Investment Management LLC increased its stake in shares of Twist Bioscience by 6.3% in the 4th quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock valued at $265,881,000 after purchasing an additional 427,274 shares in the last quarter. AEGON ASSET MANAGEMENT UK Plc acquired a new position in Twist Bioscience in the 4th quarter worth about $11,956,000. Finally, Norges Bank purchased a new position in Twist Bioscience during the fourth quarter worth approximately $10,766,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.